The low‐abundance transcriptome reveals novel biomarkers, specific intracellular pathways and targetable genes associated with advanced gastric cancer

Bizama, Carolina; Benavente, Felipe; Salvatierra, Edgardo; Gutiérrez-Moraga, Ana; Espinoza, Jaime A.; Fernández, Elmer; Roa, I.; Mazzolini, Guillermo; Sagredo, E; Gidekel, Manuel; Podhajcer, Osvaldo L.

doi:10.1002/ijc.28405

Cited by 32 publications

(21 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, an elevated serum level of CEA (CEACAM5) was associated with survival of patients with PaCa (Tas et al, 2013). Elevated intracytoplasmic LAMA3 has been observed in gastric cancer tissue samples (Bizama et al, 2014). Another mass spectrometric investigation found elevated serum levels of CP in the serum of PaCa patients (Hanas et al, 2008).…”

Section: Discussionmentioning

confidence: 95%

Retraction: “Identification of Novel Biomarkers for Pancreatic Cancer Using Integrated Transcriptomics With Functional Pathways Analysis” by Zhang, X., Tong, P., Chen, J., Pei, Z., Zhang, X., Chen, W., Xu, J. and Wang, J.

Zhang

Tong

Chen

et al. 2016

Journal Cellular Physiology

View full text Add to dashboard Cite

The above article from the Journal of Cellular Physiology, published online on 10 March 2016 in Wiley Online Library as Early View (http://onlinelibrary.wiley.com/enhanced/doi/10.1002/jcp.25353/), has been retracted by agreement between Gary Stein, the journal's Editor-in-Chief, and Wiley Periodicals, Inc. The retraction has been agreed following an investigation at the University of Texas, MD Anderson Cancer Center, which confirmed that the article was submitted and approved for publication by Dr. Jin Wang without acknowledgement of NIH funding received or the consent and authorship of Dr. Ann Killary and Dr. Subrata Sen, with whom the manuscript was originally drafted.

show abstract

Section: Discussionmentioning

confidence: 95%

Retraction: “Identification of Novel Biomarkers for Pancreatic Cancer Using Integrated Transcriptomics With Functional Pathways Analysis” by Zhang, X., Tong, P., Chen, J., Pei, Z., Zhang, X., Chen, W., Xu, J. and Wang, J.

Zhang

Tong

Chen

et al. 2016

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…IRS2 is dysregulated and acts as an oncogene in many solid tumors such as colorectal cancer, gastric cancer, and breast cancer. [22][23][24][25] Moreover, IRS2 is remarkably up-regulated and involved in the malignant progression of ovarian cancer. 17 The activation of PI3K/Akt pathway involved in many tumor pathological processes in tumor cells such as proliferation, apoptosis, and chemotherapeutics resistant.…”

Section: Discussionmentioning

confidence: 99%

Demethoxycurcumin inhibited human epithelia ovarian cancer cells’ growth via up-regulating miR-551a

Sha²

2017

Tumour Biol.

View full text Add to dashboard Cite

Curcumin is a natural agent that has ability to dampen tumor cells' growth. However, the natural form of curcumin is prone to degrade and unstable in vitro. Here, we demonstrated that demethoxycurcumin (a curcumin-related demethoxy compound) could inhibit cell proliferation and induce apoptosis of ovarian cancer cells. Moreover, IRS2/ PI3K/Akt axis was inactivated in cells treated with demethoxycurcumin. Quantitative real-time reverse transcription polymerase chain reaction demonstrated that miR-551a was down-regulated in ovarian cancer tissues and ovarian cancer cell lines. Over-expression of miR-551a inhibited cell proliferation and induced apoptosis of ovarian cancer cells, whereas down-regulation of miR-551a exerted the opposite function. Luciferase assays confirmed that there was a binding site of miR-551a in IRS2, and we found that miR-551a exerted tumor-suppressive function by targeting IRS2 in ovarian cancer cells. Remarkably, miR-551a was up-regulated in the cells treated with demethoxycurcumin, and demethoxycurcumin suppressed IRS2 by restoration of miR-551a. In conclusion, demethoxycurcumin hindered ovarian cancer cells' malignant progress via up-regulating miR-551a.

show abstract

“…Li et al, 2012). Recent studies indicate that insulin receptor substrate 2 (IRS2) is an oncogene in many solid tumors such as colorectal cancer, gastric cancer, and breast cancer (Bizama et al, 2014;F. Huang et al, 2015;Yamashita, Tsujino, Moriguchi, Tatematsu, & Ushijima, 2006).…”

Section: Dmc and Mir-551amentioning

confidence: 99%

Demethoxycurcumin: A naturally occurring curcumin analogue with antitumor properties

Hatamipour

Ramezani

Tabassi

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

The eradication of cancer in a patient remains an elusive challenge despite advances in early detection and diagnosis, chemo- and immunotherapy, pinpoint radiation treatments, and expert surgical intervention. Although significant gains have been made in our understanding of cancer cell biology, a definite cure for most cancers does not exist at present. Thus, it is not surprising that the research and medical communities continue to explore the importance and therapeutic potential of natural products in their multimodality cancer treatment approach. Curcuminoids found in turmeric are one such class of natural products that have been extensively investigated for their potential to halt the progression of cancer cell proliferation and, more important, to stop metastasis from occurring. In this review, we examine one curcuminoid (demethoxycurcumin [DMC]) largely because of its increased stability and better aqueous solubility at physiological pH, unlike the more well-known curcuminoid (curcumin), which is largely unabsorbed after oral ingestion. The present review will focus on the signaling pathways that DMC utilizes to modulate the growth, invasion, and metastasis of cancer cells in an effort to provide enhanced mechanistic insight into DMC's action as it pertains to brain, ovarian, breast, lung, skin, and prostate cancer. Additionally, this review will attempt to provide an overview of DMC's mechanism of action by modulating apoptosis, cell cycle, angiogenesis, metastasis, and chemosensitivity. Lastly, it is hoped that increased understanding will be gained concerning DMC's interactive role with microRNA-551a, 5' adenosine monophosphate-activated protein kinase, nuclear factor-κB, Wnt inhibitory factor-1, and heat shock protein 70 to affect the progression of cancer.

show abstract

The low‐abundance transcriptome reveals novel biomarkers, specific intracellular pathways and targetable genes associated with advanced gastric cancer

Cited by 32 publications

References 42 publications

Retraction: “Identification of Novel Biomarkers for Pancreatic Cancer Using Integrated Transcriptomics With Functional Pathways Analysis” by Zhang, X., Tong, P., Chen, J., Pei, Z., Zhang, X., Chen, W., Xu, J. and Wang, J.

Retraction: “Identification of Novel Biomarkers for Pancreatic Cancer Using Integrated Transcriptomics With Functional Pathways Analysis” by Zhang, X., Tong, P., Chen, J., Pei, Z., Zhang, X., Chen, W., Xu, J. and Wang, J.

Demethoxycurcumin inhibited human epithelia ovarian cancer cells’ growth via up-regulating miR-551a

Demethoxycurcumin: A naturally occurring curcumin analogue with antitumor properties

Contact Info

Product

Resources

About